Konerman Monica A, Lok Anna S F
Department of Internal Medicine, University of Michigan Health System, Division of Gastroenterology and Hepatology, Ann Arbor, Michigan, USA.
Clin Transl Gastroenterol. 2016 Sep 22;7(9):e193. doi: 10.1038/ctg.2016.50.
Current treatment for chronic hepatitis C (CHC) is highly efficacious, well-tolerated, and of short duration for the majority of patients. Despite the dramatic advances in therapy, there remain several barriers to disease eradication. These include deficiencies in screening, diagnosis, and access to care, and high cost of the direct-acting antiviral medications. In addition, incident cases and reinfection associated with injection drug use contribute to the persistent worldwide disease burden. This article will review the current CHC treatments, and outline the remaining gaps in therapy and barriers to disease eradication.
目前，慢性丙型肝炎（CHC）的治疗对大多数患者而言疗效显著、耐受性良好且疗程较短。尽管治疗取得了巨大进展，但在根除疾病方面仍存在若干障碍。这些障碍包括筛查、诊断和获得治疗方面的不足，以及直接作用抗病毒药物的高昂成本。此外，与注射吸毒相关的新发病例和再感染加重了全球持续存在的疾病负担。本文将综述目前的CHC治疗方法，并概述治疗中仍存在的差距以及根除疾病的障碍。
